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Abstract
Mitochondrial disorders (MDs) are inherited multi-organ diseases
with variable phenotypes. Inclusion body myositis (IBM), a
sporadic inflammatory muscle disease, also shows mitochondrial
dysfunction. We investigated whether primary and secondary
MDs modify metabolism to reveal pathogenic pathways and
biomarkers. We investigated metabolomes of 25 mitochondrial
myopathy or ataxias patients, 16 unaffected carriers, six IBM
and 15 non-mitochondrial neuromuscular disease (NMD) patients
and 30 matched controls. MD and IBM metabolomes clustered
separately from controls and NMDs. MDs and IBM showed
transsulfuration pathway changes; creatine and niacinamide
depletion marked NMDs, IBM and infantile-onset spinocerebellar
ataxia (IOSCA). Low blood and muscle arginine was specific for
patients with m.3243A>G mutation. A four-metabolite blood
multi-biomarker (sorbitol, alanine, myoinositol, cystathionine)
distinguished primary MDs from others (76% sensitivity, 95%
specificity). Our omics approach identified pathways currently
used to treat NMDs and mitochondrial stroke-like episodes and
proposes nicotinamide riboside in MDs and IBM, and creatine in
IOSCA and IBM as novel treatment targets. The disease-specific
metabolic fingerprints are valuable “multi-biomarkers” for diag-
nosis and promising tools for follow-up of disease progression
and treatment effect.
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Introduction
Mitochondrial disorders (MDs) are the most common group of
inherited metabolic diseases, with exceptional clinical variability.
Globally, their minimum birth prevalence is 1 in 2000–5000 individ-
uals (Thorburn, 2004; Gorman et al, 2016). The adult forms present
most commonly with neurological or muscular symptoms (Suoma-
lainen, 2011), but their diagnosis is challenging, and treatment
options are scarce. Furthermore, the molecular mechanisms of
tissue specificity and clinical variability in MDs are unknown. Mito-
chondrial dysfunction is also a characteristic sign of inclusion body
myositis (IBM), which is a sporadic inflammatory muscle disease,
the most common acquired myopathy in the elderly with a preva-
lence of 2–4:100,000 in Nordic countries (Lindgren et al, 2017).
Whether the respiratory chain deficiency in IBM contributes to the
disease progression is unknown.
Recent data from disease models highlight whole-organismal
metabolic remodelling in MDs, and importantly, these aberrant
pathways are amenable for interventions with metabolically active
cofactors, such as NAD+ precursor vitamin B3 (Khan et al, 2014).
In mice with adult-onset mitochondrial myopathy, metabolomics
analysis identified major remodelling of folate-driven one-carbon
(1C) metabolism, metabolite methylation and transsulfuration
(Nikkanen et al, 2016; Khan et al, 2017). In these mice and in a
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mouse model for infantile-onset spinocerebellar ataxia (IOSCA),
metabolic remodelling shifted the whole-cellular dNTP pools in the
affected tissues, with potential to contribute to the mtDNA instabil-
ity in these disorders.
We report here disease-specific metabolomic fingerprints present
in the blood and muscle of patients with different primary and
secondary mitochondrial disorders, with potential treatment targets,
biomarkers and pathogenic pathways.
Results
Metabolomic analysis of blood reveals disease-specific
biomarker profiles
We performed high-throughput targeted semiquantitative analysis
of 94 metabolites in blood samples of patients with mtDNA mainte-
nance disorders (IOSCA; mitochondrial recessive ataxia syndrome
[MIRAS]; progressive external ophthalmoplegia/mitochondrial
myopathy [PEO]), or defect in mitochondrial translation (mitochon-
drial myopathy, encephalomyopathy, lactic acidosis and stroke-like
episodes [MELAS]/maternally inherited diabetes and deafness
[MIDD]); as well as of IBM patients, MIRAS carriers and non-mito-
chondrial neuromuscular disease (NMD) patients (Table 1, Dataset
EV1). The patient and control groups were analysed by the partial
least squares–discriminant analysis (PLS-DA; Figs 1 and 2). Metabo-
lites with the highest separation power in PLS-DA were ranked by
variable importance in projection (VIP) scores (Figs 1 and 2),
described below for each disease.
Infantile-onset spinocerebellar ataxia blood metabolome clustered
separately from the controls (Fig 1A). The metabolic profile of this
epileptic encephalohepatopathy showed a strong component of
creatine, bile acid and transsulfuration pathway changes. Low
amounts of creatinine (fold change [FC] 1.6, P < 0.001), the secreted
breakdown product of creatine, suggested increased creatine turnover,
which was also supported by significantly increased creatine/
creatinine ratio (Fig 3A), despite the increased amount of creatine in
the blood (FC +1.9, P = 0.017). Decreased steady-state kynurenate (FC
2.2, P = 0.003) and niacinamide (NAM; FC 2.0, P = 0.013; Fig 1A)
pointed to altered NAD+ synthesis pathway and an increase in NAD+
demand. The serine-driven transsulfuration pathway (Nikkanen et al,
2016) imbalance was marked by increased upstream metabolites,
serine (FC +1.3, P = 0.013), glutamate (FC +2.4, P < 0.001) and
cystathionine (FC +1.9, P = 0.003), but depletion of transsulfuration-
dependent taurine (FC 1.6, P = 0.002) and reduced form of
glutathione (FC 2.2, P = 0.063). Two bile acids, glycocholic acid
(GCA; FC +2.4, P = 0.003) and taurine-conjugated taurochenodeoxy-
cholic acid (TCDCA; FC +2.6, P = 0.015), were increased (Fig 1A).
Glutathione depletion indicates decreased potential for antioxidant
capacity in IOSCA. Additionally, we analysed a blood sample of an
IOSCA child patient (four years of age) who showed high creatine/
creatinine ratio and low taurine and kynurenate (Fig 3B). The
significant depletion of kynurenate and the significant depletion of
niacinamide are both consistent with depletion of NAD+.
Mitochondrial recessive ataxia syndrome blood metabolome
clustered separately from controls. The patients showed significant
increase in carbohydrate derivatives, i.e., sorbitol (FC +6.2,
P < 0.0001), glucuronate (FC +1.4, P = 0.014) and myoinositol (FC
+1.2, P = 0.017; Figs 1B and 3A). Other changes included increased
alanine (FC +1.4, P = 0.002) and decreased lysine (FC 1.2,
P = 0.002) and carnosine (FC 1.4, P = 0.034), involved, e.g., in
inactivation of methylglyoxal, a product of high sugars. Similar to
IOSCA, cystathionine was increased (FC +1.5, P = 0.004; Fig 1B),
whereas other transsulfuration or creatine metabolites were not
significantly changed (Fig 3A).
In PEO patients, the blood metabolome clustered separately from
controls (Fig 1C). The significantly changed metabolites included
elevated cystathionine (FC +4.1, P < 0.001), phosphoethanolamine
(PE; FC +1.5, P = 0.005), glutamine (FC +1.2, P = 0.002) and
sorbitol (FC +2.1, P = 0.006; Figs 1C and 3A). Overall, PEO blood
showed a wide upregulation of amino acids and purine precursors
(xanthine and xanthosine; both FC +1.5) as previously reported
(Ahola et al, 2016; Nikkanen et al, 2016) and an increase in NAD+
synthesis pathway (kynurenine [FC +1.3, P < 0.001]; 3-hydroxy-DL-
kynurenine [FC +2.0, P = 0.004]; Fig 1C). Furthermore, unmethy-
lated metabolite precursor of creatine, guanidinoacetic acid (GAA;
FC +1.5, P = 0.012; Fig 1C), was increased, suggesting deficient
metabolite methylation.
The MELAS/MIDD blood metabolome clustered separately from
the controls (Fig 1D). The results showed remarkably increased
carbohydrate derivatives: sorbitol (FC +11.1, P < 0.001), glucuronate
(FC +2.0, P < 0.001), myoinositol (FC +1.6, P = 0.003; Fig 3A) and
sucrose (FC +1.5, P = 0.035). Amino acids were in general higher
than controls, including alanine (FC +1.8, P < 0.0001), with an
exception of significantly decreased arginine (FC 1.6, P < 0.0001;
Fig 3A), which was specific for MELAS/MIDD in our material. These
changes were not explained by diabetes, as they remained MELAS/
MIDD-specific even when we compared all patients with increased
insulin resistance to normoglycemic patients (Table EV1).
We then asked whether inclusion body myositis, a sporadic
inflammatory muscle disease with secondary findings of mitochon-
drial myopathy in the muscle (respiratory chain-deficient muscle
fibres, multiple mtDNA deletions), would share blood metabolic
features with primary respiratory chain deficiencies. IBM blood
metabolome clustered separately from controls (Fig 2A). The IBM
metabolic profile was defined by elevated cystathionine (FC +2.7,
P < 0.0001), dimethylglycine (FC +2.6, P = 0.001), TCDCA (FC +4.6,
P < 0.001) and citrulline (FC +1.4, P < 0.001). The alternative
NAD+ synthesis pathway was highly upregulated: kynurenine (FC
+1.6, P = 0.002) and its hydroxylated form, 3-hydroxy-DL-kynure-
nine (FC +6.2, P < 0.001), were significantly induced; however,
niacinamide was reduced (FC 2.6, P = 0.001; Fig 2A). Further-
more, IBM showed significant increases in nucleotide synthesis
precursors (e.g., adenosine, deoxycytidine, cytidine and cytosine;
FC +2.2, +1.3, +1.5, +3.4, respectively), as well as carbohydrate
derivatives: sucrose, myoinositol and glucuronate (FC +2.8, +1.6
and +1.5, respectively; Figs 2A and 3A). Also, creatine/creatinine
ratio was significantly increased, suggesting low creatine pools
(Fig 3A). Overall, IBM blood metabolome resembled the respiratory
chain deficiencies (IBM shared 39% significantly changed metabo-
lites with PEO) rather than NMDs (IBM and NDMs shared 23% of
significantly changed metabolites).
To define which changes were specific for mitochondrial diseases
and which were general consequences of muscle disease, we anal-
ysed a group of heterogeneous non-mitochondrial neuromuscular
diseases. The PLS-DA model of NMD patients clustered separately
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from controls (Fig 2B). The NMD metabolome was discriminated by
creatine metabolism (creatine FC +2.1, P < 0.001; creatinine FC
1.8, P = 0.005) with increased creatine/creatinine ratio (Fig 3A),
supporting depleted creatine pool. Furthermore, TCDCA (FC +3.6,
P = 0.005), folic acid (FC +3.0, P = 0.005) and glutamate (FC +1.6,
P = 0.012) were increased and niacinamide (FC 1.7, P = 0.004),
spermidine (FC 1.9, P = 0.006) and histidine (FC 1.2, P = 0.006)
were reduced (Fig 2B). However, cystathionine and alanine,
increased in both primary (IOSCA, MIRAS, PEO and MELAS) and
secondary (IBM) MD patients, were not elevated in NMD patients,
or in healthy controls or MIRAS carriers (Fig 3A).
The blood metabolome of the heterozygous carriers of the recessive
MIRAS allele showed separation from controls (Fig 2C). Similar to
MIRAS patients, they had increased glucuronate (FC +1.2, P = 0.029),
sorbitol (FC +1.6, P = 0.029) and myoinositol (FC +1.3, P = 0.002;
Fig 3A) and low carnosine (FC 1.8, P < 0.001). Cystathionine and
alanine, the strongest markers of MIRAS, however, were not increased
(Fig 3A). In general, the metabolic profile of MIRAS carriers revealed
subtle but significant changes, including dimethylglycine (FC +1.8,
P < 0.0001), aspartate (FC +1.8, P < 0.0001) and cytosine (FC +1.8,
P < 0.001; Fig 2C). The results suggest that carrier status of one MIRAS
allele is not completely neutral for metabolism.
Methylation cycle and glutathione pathway are affected in
muscle of MD patients
In order to compare the blood metabolomic findings with the
primarily affected tissue to understand the tissue-specific changes, we
performed targeted semiquantitative analysis of 111 metabolites in
muscle from patients and control subjects. Mitochondrial recessive
ataxia syndrome is primarily a nervous system disorder; however, the
patients carry a small amount of multiple mtDNA deletions in their
skeletal muscle (Table 1; Hakonen et al, 2008), similar to PEO
patients. MIRAS muscle metabolome was separated from controls in
Table 1. Characteristics of mitochondrial and non-mitochondrial neuromuscular disease patients.
IOSCA (N = 5a) MIRAS (N = 9) PEO (N = 8) MELAS/MIDD (N = 5) IBM (N = 6) NMD (N = 15)
Gender (n) 2F, 3M 2F, 7M 3F, 5M 2F, 3M 3F, 3M 12F, 3M
Age of onset
(years)b
1–2 29.6 (18.0–44.0) 27.8 (21.0–35.0) 39.3 (30.0–48.0) 61.4 (49.0–83.0) 26.3 (2.0–60.0)
Age at sampling
(years)b
38.6 (33.0–42.0) 41.2 (21–52.0) 50.0 (39.0–57.0) 54.0 (39.0–68.0) 71.0 (58.0–85.0) 49.9 (23.0–77.0)
FGF21 (pg/ml)c,d – 132.5 (51.0–279.8) 454.0 (222.0–604.3)† 562.0 (188.5 –2569.0)‡ 57.0 (34.3–287.8) 114.0 (24.0–190.0)
Inheritance
disease gene,
amino acid
change
AR, TWNK
p. Y508C
AR, POLG
p. W748S+E1143G
AD, TWNK 13AA dup
(TWNK-PEO); AR,
POLG p. A1105T/N468D
(POLG-PEO); Sporadic,
mtDNA single
deletion (Del-PEO)
Maternal, mtDNA
m.3243A>G, tRNALeu
(UUR)
Sporadic AD or AR, DMPK,
ZNF9, CAPN3,
PABPN1, SMN1,
TIA1 or unknown
Histological
findings in
skeletal muscle
None 1–5%
COX-/SDH+ fibres
POLG/TWNK-PEO:
5–12% COX-/SDH+;
Del-PEO: 30–60%
COX-/SDH+
5–30%
COX-/SDH+ fibres
1–8%
COX-/SDH+
fibres
Dystrophy,
hypertrophy,
normal respiratory
chain
MtDNA
consequences
MtDNA
depletion in
brain and liver
MtDNA depletion,
small amount of
heteroplasmic
multiple mtDNA
deletions in skeletal
muscle
Heteroplasmic
multiple mtDNA
deletions, or single
large mtDNA deletion
in skeletal muscle
Heteroplasmy; ~70% of
mutant mtDNA in
muscle and urine
epithelial cells
Multiple mtDNA
deletions
None
Muscle
symptoms
 /+ + ++ ++ ++
Clinical
symptoms
Childhood-onset
ataxia,
neuropathy,
athetosis,
hearing loss,
epilepsy,
hepatopathy
Ataxia, neuropathy,
epilepsy, psychiatric
symptoms, cognitive
decline, obesity/
insulin resistance
Mitochondrial
myopathy, ptosis,
progressive external
ophthalmoplegia,
exercise intolerance
Mitochondrial
myopathy,
cardiomyopathy,
diabetes mellitus,
hearing loss, stroke-like
episodes
Distal
progressive
muscle
weakness
, muscle phenotype not present; +, mild muscle phenotype; ++, primary muscle phenotype. AR, autosomal recessive; AD, autosomal dominant; COX-/SDH+,
cytochrome C oxidase-negative/succinate dehydrogenase-positive fibres; F, female; M, male; N, number; mtDNA, mitochondrial DNA.
See Dataset EV1 for raw data.
aAdditional IOSCA child patient (four years of age; Fig 2B). This patient, however, was not included in the overall statistical analysis due to lack of appropriate
age- and gender-matched control samples.
bValues represent mean with minimal and maximal age.
cValues represent median with interquartile range.
dNormal value for FGF21 ≤ 331 pg/ml (Lehtonen et al, 2016).
‡P = 0.009, †P = 0.002 (nonparametric Kruskal–Wallis test).
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Figure 1. Metabolomic fingerprints of primary mitochondrial diseases.
A–D Clustering of metabolome data in patients and controls; PLS-DA plots; VIP score plots of top 15 metabolites; volcano plots of all metabolites in blood of IOSCA (A),
MIRAS (B), PEO (C), and MELAS/MIDD (D). aSignificantly changed metabolites outside the FDR cut-off. bMetabolites not significantly changed between patients and
controls. Colours in VIP score and volcano plots indicate the same most relevant and/or significantly changed metabolites among all patient groups. C3, component
3; CDCA, chenodeoxycholic acid; GABA, c-aminobutyric acid; HIAA, 5-hydroxyindole-3-acetic acid; OH-Kyn, 3-hydroxy-DL-kynurenine; SDMA, symmetric
dimethylarginine; TCA, taurocholic acid. See Dataset EV2 for raw data.
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PLS-DA (Fig 4A). The most significantly changed metabolites (false
discovery rate [FDR] < 0.5) were the major methyl carriers, elevated
S-adenosyl-L-homocysteine (SAH; FC +1.8, P = 0.009) and reduced S-
adenosyl-L-methionine (SAM; FC 3.4, P = 0.034; Fig 4A, Dataset
EV2). This was an indication for methyl cycle imbalance in MIRAS
muscle. However, the MIRAS muscle metabolite signature did not
overlap with the blood biomarker profile (Fig 4C), e.g., low carbohy-
drate derivatives in muscle (Fig 4D), suggesting that the metabolic
changes in the blood likely reflected metabolism of another affected
tissue, such as the brain or liver; indeed, muscle manifestation in
MIRAS is mild or completely lacking.
The PEO and MELAS/MIDD patients in this study had mainly
muscle/cardiac symptoms. The PEO muscle metabolites separated
from controls in PLS-DA model (Fig 4B), and the muscle metabolic
profile revealed changes in key metabolites of the methyl cycle and
glutathione metabolism: cystathionine was remarkably increased (FC
+8.3, P = 0.009), and methionine (FC +1.5, P = 0.032) and serine (FC
+1.9, P = 0.016; Fig 4B, Dataset EV2) were elevated (FDR < 0.3).
A
B
C
Figure 2. Metabolomic fingerprints of inclusion body myositis, muscle disorders of non-mitochondrial origin and MIRAS carriers.
A–C Clustering of metabolome data in patients and controls; PLS-DA plots; VIP score plots of top 15 metabolites; volcano plots of all metabolites in blood of IBM (A),
NMD patients (B) and MIRAS carriers (C). aSignificantly changed metabolites outside the FDR cut-off. bMetabolites not significantly changed between patients and
controls. Colours in VIP score and volcano plots indicate the same most relevant and/or significantly changed metabolites among all patient groups. cAMP, cyclic
AMP; C3, component 3; CDCA, chenodeoxycholic acid; GABA, c-aminobutyric acid; HIAA, 5-hydroxyindole-3-acetic acid; IMP, inosine monophosphate; OH-Kyn,
3-hydroxy-DL-kynurenine; OH-Trp, hydroxytryptophan; SDMA, symmetric dimethylarginine. See Dataset EV2 for raw data.
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These metabolites overlapped well with the metabolites changed in
PEO blood (Fig 4C and D; Nikkanen et al, 2016). Similar to PEO,
cystathionine was increased in MELAS/MIDD muscle (FC +1.3) as
were other contributors to the transsulfuration cycle, namely gamma-
glutamyl-cysteine (c-Glu-Cys; FC +1.4), SAM (FC +1.9) and glutamate
(FC +1.2). In contrast, adenosine (FC 3.6), GAA (FC 3.4) and
betaine (FC 2.4) were reduced (Dataset EV2). The metabolites from
MELAS/MIDD blood and muscle partially overlapped (Fig 4C and D):
e.g., low arginine (blood [FC 1.6; Fig 3A] and muscle [FC 2.4;
Fig 4D]). The findings of PEO and MELAS/MIDD patients support the
conclusion that the blood metabolome reflects at least partially the
metabolome of the disease affected tissue.
Pathway analysis: transsulfuration metabolism remodelled in
mtDNA maintenance disorders
Pathway analysis of the full metabolomes of blood showed several
significantly changed pathways common to all MDs, but not to
NMDs (Fig 5 shows top 10 pathways with ≥10% metabolites
detected in the pathway; Dataset EV3). Transsulfuration pathway
A
B
Figure 3. Quantification of disease-specific single metabolites in blood.
A Relative values of single metabolites and creatine/creatinine ratios in blood of primary MD, IBM and NMD patients, and MIRAS carriers compared to controls.
B Relative values of single metabolites in blood of adult IOSCA (marked “IOSCA”) patients and one IOSCA child patient compared to controls.
Data information: All data represent mean  SD. For all individual metabolites: *P < 0.05, **P < 0.01, ***P < 0.001 (two-sample t-test). For creatine/creatinine (cr/crn)
ratio: *P = 0.022, **P = 0.005, ***P = 0.0001 (Mann–Whitney test). See Dataset EV2 for raw data.
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Figure 4. Muscle metabolomes of MIRAS, PEO and MELAS patients.
A, B Metabolomes of muscle of MIRAS (A) and PEO (B) patients; PLS-DA plots; VIP score plots of top 15 metabolites; volcano plots of all metabolites.
C Methyl cycle, transsulfuration and glutathione biosynthesis pathways changed in IOSCA, MIRAS, PEO and MELAS/MIDD patients. Circled text: metabolites changed
in blood; red, increased; blue, decreased. Coloured text: metabolites changed in muscle; red, increased; blue, decreased. Selected for MELAS muscle were metabolites
with the highest fold change.
D Relative values of metabolites in muscle of MIRAS, PEO and MELAS/MIDD patients compared to controls.
Data information: aSignificantly changed metabolites outside the FDR cut-off. bMetabolites not significantly changed between patients and controls. All data represent
mean  SD. *P = 0.031, **P = 0.008 (two-sample t-test). AMP, adenosine monophosphate; car., carnitine; Hcy, homocysteine; NAD, nicotinamide adenine dinucleotide;
TCA, taurocholic acid; UDP, uridine diphosphate. See Dataset EV2 for raw data.
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(cysteine and methionine metabolism) and amino acid biosynthesis
pathway (alanine, aspartate and glutamate biosynthesis) were aber-
rant in mtDNA expression disorders (mtDNA maintenance/transla-
tion: IOSCA, MIRAS, PEO, MELAS) and IBM (Fig 5A–E), as well as
in muscle of PEO patients (Fig 5G), the cysteine and methionine
metabolism being among the top four significant pathways in blood,
and folate metabolism being also prominent in MIRAS muscle
(Fig 5H). Transsulfuration pathway or the amino acid biosynthesis
pathway was not significantly changed in NMD patients (Fig 5F).
Purine/pyrimidine synthesis was common to muscle-manifesting
disorders including NMD (Fig 5C–F; Dataset EV3).
Sorbitol, myoinositol, alanine and cystathionine: a
multi-biomarker for MDs
We then tested the performance of metabolites as disease biomark-
ers in a pooled set of MD patients (MIRAS, PEO and MELAS/MIDD
patients; n = 20), asking which metabolites would show the best
sensitivity and specificity for MD to distinguish them from healthy
controls (n = 30). By receiver operating characteristic (ROC) curve
analysis, the top four significant metabolites with the highest
area under curve (AUC) were sorbitol 0.81 (95% confidence interval
[CI] 0.68–0.94, P = 0.0003), alanine 0.81 (95% CI: 0.67–0.94,
P = 0.0003), myoinositol 0.79 (95% CI: 0.66–0.91, P = 0.0007) and
cystathionine 0.78 (95% CI: 0.65–0.91, P = 0.001; Fig 6A), which
we together call “multi-biomarker” for MDs. We then compared it
to conventional blood biomarkers: lactate and pyruvate, and fibrob-
last growth factor 21 (FGF21), a serum biomarker of muscle-mani-
festing MDs. For the same set of patients and controls, FGF21 had
the highest AUC 0.87 (95% CI: 0.74–0.99, P = 0.0001), followed by
lactate 0.86 (95% CI: 0.76–0.97, P = 0.0001) and pyruvate 0.78
(95% CI: 0.64–0.93, P = 0.0017; Fig 6A). We then compared sensi-
tivity of the four metabolites and the conventional blood biomarkers
to identify MDs. FGF21 showed the highest sensitivity of all (68%;
95% CI: 43.5–87.4; Fig 6A), when including all MD patients, and
when considering only muscle-manifesting MDs—known to induce
FGF21 secretion—its sensitivity in this material was 91% (95% CI:
66.4–100.0; Fig EV1B). Lactate and pyruvate showed sensitivity
45% (95% CI: 23.1–68.5) and 13% (95% CI: 1.6–38.4), respectively,
and specificity 97% (95% CI: 82.8–99.9; Fig 6A). As single metabo-
lites, sorbitol and alanine showed sensitivity of 55% (95% CI: 31.5–
76.9) and specificity 97% (95% CI: 82.8–99.9), and for myoinositol
and cystathionine, the sensitivity was 25% (95% CI: 8.7–49.1), and
specificity 93.3% (95% CI: 77.9–99.2) and 97% (95% CI: 82.8–99.9),
respectively (Fig 6A), to identify MDs. However, when we combined
the four metabolites together and calculated mean centroid values
from sorbitol, alanine, cystathionine and myoinositol for all patients
and controls, the primary and secondary MDs differed significantly
from controls, MIRAS carriers and NMDs (Fig 6B). The sensitivity of
this blood multi-biomarker to find primary MDs raised to 76% (95%
CI: 54.9–90.6) and specificity to 95% (95% CI: 83.1–99.4) with AUC
0.94 (95% CI: 0.88–0.995, P = 0.0001; Fig 6B).
Discussion
We report here disease-specific metabolomic fingerprints, detectable
in blood, of primary mitochondrial muscle and brain disorders,
inclusion body myositis with secondary mitochondrial defects, and
a mixed group of severe primary muscle dystrophies/atrophies. Our
evidence indicates the following: (i) All the disease groups show
blood metabolic fingerprints that cluster separately from healthy
controls, indicating the potential of metabolomic fingerprints as
multi-biomarkers for diagnosis, follow-up of disease progression
and treatment effect; (ii) IBM causes similar global metabolomic
changes as primary mitochondrial myopathies reflected in blood,
suggesting that metabolic strategies for intervention may be shared
in these disease groups; (iii) Heterozygous carriership for the reces-
sive MIRAS allele, common in Western populations (Hakonen et al,
2005; Winterthun et al, 2005; population frequency 1:84 in Finns
and 1:100 in Norwegians; www.sisuproject.fi) is not metabolically
neutral; (iv) Our omics approach identified known therapy targets,
already in clinical use [arginine in MELAS/MIDD blood and muscle
(Koga et al, 2005; Koenig et al, 2016); creatine in NMDs; Kley et al,
2013)] and identified new potential targets for treatment of IOSCA
(creatine, glutathione [N-acetyl-cysteine] and NAD+ [nicotinamide
riboside] supplementation) and IBM (creatine supplementation),
proposing that targeted metabolomic analysis may not only be valu-
able for mechanistic studies, but also suggest metabolic targets for
treatment trials.
The pathogenic mechanism of sporadic IBM, the inflammatory
and treatment-resistant muscle disease is still unknown, although it
is one of the most frequently encountered muscle diseases in neurol-
ogy clinics. Typical findings include inflammation, increased number
of autophagosomes and characteristics of mitochondrial myopathy:
respiratory chain-deficient muscle fibres and accumulation of multi-
ple mtDNA deletions (Oldfors et al, 1995). These mitochondrial
changes are considered to be a secondary consequence of IBM patho-
genesis, probably due to lower turnover of mitochondria as a result
of insufficient macroautophagy/mitophagy (Askanas et al, 2015),
but whether mitochondrial dysfunction in IBM has functional conse-
quences has been unknown. Our finding of the similarity of blood
metabolomes of the primary MDs and IBM suggests that mitochon-
drial dysfunction drives the metabolic changes in IBM reflected in
the blood. These findings propose that intervention strategies of
mitochondrial biogenesis, NAD+-boosters or rapamycin, suggested
to be beneficial for mitochondrial myopathies in mice (Viscomi et al,
2011; Yatsuga & Suomalainen, 2012; Cerutti et al, 2014; Khan et al,
2014, 2017), should be evaluated also in IBM.
A prominent metabolic pattern in different MDs in blood and
muscle pointed to aberrant folate-driven 1C-cycle, which is the
major cellular anabolic biosynthesis pathway, providing 1C-units
for growth and repair. The pathways that feed from this cycle
depend on cell-type needs and include de novo purine synthesis,
methyl cycle, genome and metabolite methylation (creatine and
phospholipid synthesis) and transsulfuration (cysteine metabo-
lism, glutathione and taurine synthesis). These 1C-pathways were
recently discovered to be remodelled in cells and mice with
mtDNA maintenance defects, leading to dNTP pool imbalance, as
well as induced glucose-driven de novo serine biosynthesis with
glucose carbon flux towards glutathione synthesis (Bao et al,
2016; Nikkanen et al, 2016). The most prominent hits in IOSCA,
MIRAS, PEO, MELAS and IBM pointed to aberrant transsulfura-
tion pathway, with the most significant depletion of taurine and
reduced form of glutathione found in IOSCA. Related findings
were observed also in muscle of MIRAS patients, with more
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Figure 5. Pathway analysis of blood and muscle metabolites.
A–F Changed metabolic pathways in blood of IOSCA (A), MIRAS (B), PEO (C), MELAS/MIDD (D), IBM (E) and NMD (F) patients.
G, H Changed metabolic pathways in muscle of PEO (G) and MIRAS (H) patients.
Data information: Top 10 pathways with ≥ 10% of detected metabolites per pathway are shown. *5% metabolite coverage in the pathway. bio., biosynthesis; deg.,
degradation; metab., metabolism. See Dataset EV3 for raw data.
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emphasis in the proximal folate-pool and methyl cycle: low
methyl-donor S-adenosyl-methionine and high S-adenosyl-homo-
cysteine point to lowered methylation capacity. Increased levels
of carbohydrate-derived metabolites (sorbitol, myoinositol), a sign
of high glucose uptake in the muscle, is also known to challenge
regeneration of reduced glutathione (Brownlee, 2001). These
changes in mtDNA maintenance diseases point to a challenged
glutathione supply and suggest that N-acetyl-cysteine supplemen-
tation, providing cysteine for glutathione and taurine synthesis,
could be tried as a metabolic bypass therapy.
Our unbiased screen identified creatine depletion in NMD
patients, which was an interesting proof of principle, as a Cochrane
review found creatine supplementation to be useful for muscle
dystrophies (Kley et al, 2013). However, similarly low global crea-
tine pool, represented by the blood creatine/creatinine ratio, was
found to be present in IBM and also in IOSCA, despite the fact that
IOSCA patients do not show any muscle phenotype (Lo¨nnqvist et al,
1998) or low muscle mass (Park et al, 2013). Although muscle inac-
tivity can contribute to increased creatine/creatinine ratio in blood
of NMD and IBM patients, the increased creatine/creatinine ratio in
adult IOSCA patients, as well as in the IOSCA child patient who is
motorically as active as her age-mates, suggests an important role of
creatine metabolism in the disease pathogenesis. Creatine synthesis
is a major methyl group user, utilizing the same 1C/methyl pool as
transsulfuration cycle, and thus, the creatine supplementation in
IOSCA and IBM should be studied.
Our omics approach highlighted a deficiency of arginine to be
specific for MELAS/MIDD in both blood and muscle, as the only
significantly decreased amino acid. Low arginine has previously
been reported in blood of MELAS patients with stroke-like episodes
(Koga et al, 2005), but not in MIDD or in patients’ tissues. L-argi-
nine supplementation has been reported to prevent and treat
MELAS-associated stroke-like episodes in open-label trials (Koga
et al, 2005, 2007; Naini et al, 2005; El-Hattab et al, 2012) and was
recently recommended as a treatment (Koenig et al, 2016). Arginine
acts as a precursor for nitric oxide (NO) that has a major role in
muscle relaxation of small blood vessels (Koga et al, 2005), and
arginine deficiency and the consequent NO deficiency could contri-
bute to the pathogenesis of stroke-like episodes in MELAS. Our
unbiased metabolomics approach supports arginine deficiency to be
also a feature of MIDD. This was a second interesting proof of prin-
ciple of the potential of an omics approach in identifying therapeuti-
cally valuable metabolic targets.
We found the full set of ~100 metabolites very informative, and a
previous study in mitochondrial myopathy mice supported the
biomarker potential of a semiquantitative metabolomic analysis in
A
B
Figure 6. Blood metabolites as biomarkers for mitochondrial diseases.
A ROC curves for individual metabolites sorbitol, alanine, myoinositol and cystathionine (left) and conventional blood biomarkers lactate and pyruvate, and cytokine
FGF21 (right) in blood of MIRAS, PEO and MELAS/MIDD patients (n = 20) compared to controls (n = 30).
B ROC curve for the combined “multi-biomarker” of sorbitol/alanine/myoinositol/cystathionine for primary MDs compared to controls (left); mean centroids for MD, IBM
and NMD patients, and MIRAS carriers compared to controls (right).
Data information: ROC analysis: AUC of sorbitol 0.81 (95% CI: 0.68–0.94, P = 0.0003), alanine 0.81 (95% CI: 0.66–0.94, P = 0.0003), myoinositol 0.79 (95% CI: 0.66–0.91,
P = 0.0007) and cystathionine 0.78 (95% CI: 0.65–0.91, P = 0.001); AUC of conventional biomarkers: lactate 0.86 (95% CI: 0.76–0.97, P = 0.0001) and pyruvate 0.78 (95%
CI: 0.64–0.93, P = 0.0017), and FGF21 0.87 (95% CI: 0.74–0.99, P = 0.0001). AUC of “multi-biomarker” 0.94 (95% CI: 0.88–0.995, P = 0.0001). Mean centroid data represent
mean  SD. **P < 0.01, ***P < 0.001 (1-way ANOVA with Dunnett’s multiple comparison test). See Dataset EV2 for raw data.
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follow-up of therapy effect: after treatment with rapamycin, the meta-
bolomes of wild-type and affected mice shifted from separate clusters
to overlap (Khan et al, 2017). However, we also identified here a
minimal set of four individual metabolites that were enough to distin-
guish MDs from other muscle-manifesting disorders as a “multi-
biomarker”: cystathionine, sorbitol, myoinositol and alanine. Sorbitol
and myoinositol have not been reported previously to be changed in
MDs. Elevated cystathionine was found in single patients with mtDNA
depletion syndrome (Tadiboyina et al, 2005; Mudd et al, 2012), but
not in blood samples of patients with Leigh syndrome (Thompson
Legault et al, 2015), caused by a structural defect of the respiratory
chain. Alanine is a standard blood biomarker in MDs (Haas et al,
2008), but is also found increased in other conditions, including
sepsis, tetraspasticity, hyperinsulinism, chronic thiamine deficiency or
as a side effect of valproic acid treatment (Thabet et al, 2000; Noguera
et al, 2004; Thauvin-Robinet et al, 2004; Morava et al, 2006). Despite
lacking sensitivity as single metabolites, their power increases as a
combined multi-biomarker. We propose their blood values to be
tested in follow-up of disease progression and therapy effect when
testing of a large-scale targeted metabolome is not feasible.
Increased carbohydrate metabolites, but not cystathionine and/
or alanine, were detected in blood of asymptomatic MIRAS carriers.
Previously, a cross-sectional screening study of asymptomatic
m.3243A>G (MELAS) mutation carriers revealed significant dif-
ferences in their urinary proteome compared to healthy controls
(Hall et al, 2015). The evidence suggests that carriership of a reces-
sive nuclear mutation or low mtDNA mutation heteroplasmy level
modestly remodels metabolism, and these changes are detectable in
blood. Whether these effects have consequences for the health of
the carriers (Hakonen et al, 2005; Winterthun et al, 2005) remains
to be studied considering the common occurrence in populations
(up to 1:84 for single mutations).
A recent study on muscle metabolomics of a dog model for Duch-
enne muscular dystrophy reported arginine and proline metabolism
as the top changed pathways (Abdullah et al, 2017), which is also
the top pathway in the blood metabolomes of our NMD patients.
These findings suggest that the blood metabolomic responses to
muscular dystrophy are conserved in species and that a semiquanti-
tative metabolomics assay—or arginine/proline content of serum—
could be useful as a multi-biomarker for treatment follow-up in
muscle dystrophies.
A limitation of our study is the small sample size of separate
patient groups, which may lead to overfitting in the PLS-DA analysis
of metabolome data. However, the groups are genetically homoge-
nous: the patients had a confirmed DNA or morphological diagnosis,
and for a rare disease material, our cohort is well representative. In
the metabolomic analysis, the patients cluster separately from their
age- and gender-matched controls. Furthermore, importantly, the
metabolomic data do not stand alone: these human results robustly
replicate previous metabolic and proteomic data obtained from dif-
ferent mouse and cell models with related defects, further validated
with independent methods in different model systems (Ost et al,
2015; Bao et al, 2016; Nikkanen et al, 2016; Ku¨hl et al, 2017). Our
results highlight the potential of targeted metabolomics of blood and
tissue samples for mechanistic studies and as biomarkers for follow-
up of disease progression and treatment effects. Importantly, our
omics screen identified targets for metabolite treatment, both verify-
ing previously known targets and suggesting novel ones for IOSCA
and IBM, disorders with few treatment options. Longitudinal follow-
up studies to assess metabolome dynamics during disease progres-
sion and therapeutic interventions are warranted.
Materials and Methods
The study was undertaken according to Helsinki Declaration and
approved by the ethical review board of Helsinki University Central
Hospital (HUCH) with written and signed informed consents from
the study subjects.
Participants
Table 1 summarizes the patient data (Dataset EV1). We obtained
plasma samples from nine MIRAS patients (OMIM #607459), and
muscle biopsy samples from five of them. All patients were
homozygous for the “MIRAS allele” (p.W748S+E1143G) in POLG,
the nuclear gene encoding the catalytic subunit of the mitochon-
drial DNA polymerase gamma. MIRAS is an autosomal recessive
disorder affecting mainly the central nervous system (CNS). The
MIRAS patients in this study manifested typically with progressive
gait disturbance, polyneuropathy, ataxia, and some with epilepsy,
but signs of muscle pathology were absent or mild (respiratory
chain-deficient muscle fibres, mtDNA deletions and blood FGF21
concentration; Table 1; Hakonen et al, 2005; Lehtonen et al,
2016). We also collected plasma from 16 non-manifesting MIRAS
family members heterozygous for the MIRAS allele (“MIRAS carri-
ers”, Dataset EV1). The MELAS (OMIM #540000)/MIDD (mater-
nally inherited diabetes and deafness; OMIM #520000) patients
carried a heteroplasmic m.3243A>G point mutation in mtDNA
tRNALeu(UUR) gene (Goto et al, 1990). Plasma samples were
obtained from five MELAS patients and muscle samples from two
patients. The patients manifested in the late adulthood (~40 years
of age) with different combinations of mitochondrial myopathy
and ragged-red fibres (RRFs), cardiomyopathy, diabetes mellitus,
hearing loss and stroke-like episodes; showed a high amount of
respiratory chain-deficient fibres in their muscle, were heteroplas-
mic for the mutant mtDNA in the skeletal muscle (range 50–90%)
and urine epithelial cells (65–80%) as determined by minise-
quencing (Suomalainen et al, 1993) and showed high FGF21
concentration in their blood (Table 1; the patients were described
in Lehtonen et al, 2016). Additionally, we utilized six serum
samples from patients with inclusion body myositis (IBM; OMIM
#147421). IBM is typically a sporadic muscle disease characterized
by progressive weakness and wasting of distal muscles, the
muscle sample showing inflammation and typical findings of
mitochondrial myopathy—a high amount of respiratory chain-defi-
cient muscle fibres—but normal level of blood FGF21 (Table 1;
Suomalainen et al, 2011; Lehtonen et al, 2016). We therefore
consider IBM a secondary mitochondrial disease. As “non-mito-
chondrial disease controls”, we analysed serum metabolomes
from 15 patients with different neuromuscular diseases (NMDs;
Suomalainen et al, 2011; Lehtonen et al, 2016): Becker’s muscle
dystrophy (DMD), myotonic dystrophy type I (DMPK) and II
(ZNF9), motoneuron disease (unknown), muscle weakness
(CAPN3), oculopharyngeal muscular dystrophy (PABPN1), late-
onset Pompe’s disease (GAA), spinal muscular atrophy type II
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(SMN1) and III (unknown), and Welander’s muscular dystrophy
(TIA1; Table 1). To compare the parallel disease-specific signatures
of all available genetically defined mitochondrial disease groups,
we also re-analyse metabolomic data from blood and muscle of
patients with progressive external ophthalmoplegia (PEO) and
infantile-onset spinocerebellar ataxia (IOSCA; Nikkanen et al,
2016). The PEO cohort included patients with autosomal dominant
PEO with TWNK mutations (TWNK-PEO, OMIM #609286; Spelbrink
et al, 2001), patients with recessive mutations in POLG (POLG-PEO,
OMIM #157640; Luoma et al, 2004) and patients with a sporadic
single heteroplasmic large mtDNA deletion (Del-PEO; Table 1).
These patients had typical PEO and mitochondrial myopathy as their
uniform clinical phenotype, and our previous studies have indicated
PEO patients to respond remarkably similarly to treatments (Ahola
et al, 2016), strongly suggesting similarity in underlying pathophysi-
ological changes. Therefore, we grouped the PEO patients as a single
study group, despite their different genotypes. Muscle samples were
obtained from three TWNK-PEO patients and two Del-PEO patients
(Dataset EV1). IOSCA (OMIM #271245) is caused by a homozygous
recessive mutation in TWNK (Nikali et al, 2005). Additionally, we
were able to obtain a plasma sample from an IOSCA child patient
(age 4 years). Plasma samples were obtained from 30 healthy
volunteers (mean age 42 years, 22–63 years [min–max age]), serum
samples from 10 healthy volunteers (mean age 41 years, 29–
57 years [min-max age]) and muscle samples from 10 healthy
volunteers (mean age 44 years, 23–55 years [min–max age]).
Blood and muscle samples
Blood samples were taken after an overnight fast during an outpa-
tient visit at Helsinki University Hospital. Serum (no coagulant
included) and plasma (with K2-EDTA) were immediately separated
from the peripheral venous blood by centrifugation at 3,000 g at
+4°C for 15 min and stored at 80°C until analysis. Muscle
samples were taken by needle biopsy from vastus lateralis muscle
under local anaesthesia, snap frozen and stored at 80°C until
analysis.
Targeted metabolomics analysis
Serum/plasma and muscle metabolites were extracted and
analysed as previously described (Khan et al, 2014; Nikkanen
et al, 2016; Kolho et al, 2017; Nandania et al, 2018). Briefly,
metabolites were extracted from frozen muscle samples (10–
35 mg) homogenized with extraction solvent (1:30, sample:
solvent) and 100 ll of serum/plasma samples (1:4, sample:
solvent), separated with Waters ACQUITY Ultra-Performance Liquid
Chromatography and analysed with triple quadrupole mass spec-
trometry. Complete method description and instrument parameters,
including thorough validation of the analytical method according
to EMA guidelines (European Medicines Agency 2011), are
reported separately (Nandania et al, 2018). In blood, 94 metabo-
lites were measured. However, at the time when we performed the
muscle metabolite analysis, our metabolite set was updated to 111,
including methionine intermediates and acylcarnitines (Dataset
EV2).
Statistical analysis
Targeted metabolomics data were analysed using MetaboAnalyst
3.0 (www.metabolanalyst.ca; Xia et al, 2009, 2015). The data were
log-transformed and autoscaled before statistical analysis. Plasma
metabolomes of MIRAS (n = 9), PEO (n = 6), MELAS (n = 5) and
MIRAS carriers (n = 16) were compared to plasma of controls
(n = 30). Serum metabolomes of IOSCA (n = 5), IBM (n = 5) and
NMD (n = 15) patients were compared to serum of controls
(n = 10). Individual metabolite values are shown for the one addi-
tional IOSCA child patient (Fig 3B), to show the relevance of IOSCA
findings in early- vs late-stage disease. However, this child patient
was not included in the overall statistical analysis of adult IOSCA
patients due to lack of appropriate age- and gender-matched control
samples. Muscle metabolomes of MIRAS (n = 5) and PEO (n = 5)
patients were compared to muscle of controls (n = 10 and n = 7,
respectively). Differences between control and patient groups were
tested with univariate analysis, two-sample t-test. Metabolites were
tested for false positivity (FDR) with Benjamini–Hochberg method
with a critical value of 0.2 (Dataset EV2). For multivariate regres-
sion, we performed partial least squares–discriminant analysis (PLS-
DA) with variable importance in projection (VIP). The cross-valida-
tion of PLS-DA model was done with leave-one-out cross-
validation (LOOCV) method (Table EV2; MetaboAnalyst 3.0). Due
to the small amount of female MIRAS and PEO patients, we tested
the effect of gender on blood metabolome among our controls
(females n = 16, males n = 14). Three metabolites were signifi-
cantly changed between male and female controls (Fig EV1A);
however, their FDR was >0.7. Therefore, we included all male and
female controls in MIRAS and PEO blood analysis (all figures). Due
to small amount of MELAS muscle samples (n = 2), statistical anal-
ysis was not possible (Fig 4). Global test was used for the pathway
The paper explained
Problem
Mitochondrial disorders are rare, diagnosis challenging and patho-
physiology poorly known. Studies in mice with mitochondrial myopa-
thy suggested major systemic metabolomic changes, but human
metabolomic studies in genetically and clinically uniform patient
groups are unavailable. Furthermore, no knowledge exists of meta-
bolic changes in inclusion body myositis (IBM), a common sporadic
muscle disease with secondary mitochondrial myopathy findings.
Lastly, sensitive and specific blood biomarkers are lacking.
Results
We investigated a representative group of mitochondrial myopathy
and ataxia patients, unaffected MIRAS carriers, as well as patients
with IBM and non-mitochondrial neuromuscular disease by metabo-
lomic analysis. We identified distinct disease-group-specific metabo-
lomic fingerprints in blood and muscle. IBM clustered together with
mitochondrial myopathies, proposing important contribution of mito-
chondrial dysfunction in IBM-related muscle weakness. A novel four-
metabolite multi-biomarker (sorbitol, alanine, cystathionine and
myoinositol) distinguished primary and secondary mitochondrial
disorders from other groups.
Impact
Our omics data highlight the potential of metabolomic fingerprints in
blood as multi-biomarkers for diagnosis, disease progression and
treatment effect.
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enrichment analysis, and relative-betweenness centrality method
was used for pathway topology analysis (MetaboAnalyst 3.0;
Dataset EV3). Sensitivity and specificity were analysed by the
univariate ROC analysis, and AUC was determined (GraphPad
PRISM 6; GraphPad Software, La Jolla, CA). A mean centroid for
metabolites with the highest AUC (cystathionine, alanine, sorbitol
and myoinositol) was calculated for each patient as an overall
predictive value (Dataset EV2) and tested with one-way ANOVA
and Dunnett’s multiple comparison test (GraphPad PRISM 6). The
mean centroid values of the four-metabolite biomarker of controls,
IOSCA, MIRAS, PEO and MELAS, were used for sensitivity and
specificity determination by ROC curve, and AUC was calculated
(GraphPad PRISM 6). Serum FGF21 was tested with Kruskal–Wallis
test with Dunn’s multiple comparisons test (GraphPad PRISM 6).
Creatine/creatinine ratio between controls and patients was tested
with Mann–Whitney test (GraphPad PRISM 6; Dataset EV2).
Data availability
The datasets produced in this study are available in the following
databases:
Metabolomics data: PeptideAtlas accession number: PASS01255
(http://www.peptideatlas.org/PASS/PASS01255).
Expanded View for this article is available online.
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